High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Persistent/Relapsed Ovarian Cancer
| Autor: | Daesik Hong, Hyun Soo Kim, Sung Kyu Park, Jong Ho Won, Hee Sook Park, Seung Ho Baick, Joon Sung Park, Hugh C. Kim, Chan Kyu Kim, So Eun Kim, Kyu Taeg Lee |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Hematopoietic stem cell transplantation medicine.disease Autotransplantation Surgery law.invention Randomized controlled trial Refractory law Internal medicine Bacteremia medicine Progression-free survival Ovarian cancer business |
| Zdroj: | Cancer Research and Treatment. 34:439-443 |
| ISSN: | 2005-9256 1598-2998 |
| DOI: | 10.4143/crt.2002.34.6.439 |
| Popis: | Purpose High dose chemotherapy (HDC) is increasingly being used for ovarian cancer. Although early studies of autotransplantation for advanced ovarian cancer have been encouraging, most reported series were small, and no randomized trials have been reported. HDC and autologous hematopoietic stem cell transplantation were rarely performed in patients with ovarian cancer in Korea, and no results have been reported with the exception of one case report. Materials and methods We retrospectively analyzed 10 patients with refractory or relapsed ovarian cancer having received HDC and autologous peripheral blood stem cell transplantation (APBSCT), between January 1996 and September 1998, at the Soon Chun Hyang and Ajou University Hospitals. Results Ten patients were treated with HDC and APBSCT. Six patients achieved complete response (CR) and 1 a partial response (PR), with a response rate of 70%. Three patients did not respond following mobilization chemotherapy, and failed to respond after HDC. The median duration of progression free survival (PFS) and overall survival (OS) were 6 (4~46) and 13 (3~50+) months, respectively. The median duration of OS of the responders following mobilization chemotherapy was 23 (8~50+) compared with 12 (3~18) months of the non- responders. With regard to the treatment related toxicity, 8 patients had neutropenic fevers, and bacteremia was documented in 4. The non-hematological toxicities were never life threatening, and there were no treatment related deaths. Conclusion HDC, followed by APBSCT, is well-tolerated patients with refractory or relapsed ovarian cancer, and following mobilization chemotherapy the responders survived longer than the non-responders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|